Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Statins' cost-effectiveness

This article was originally published in The Tan Sheet

Executive Summary

Role of statin cholesterol-lowering drugs will change if clinical trials of alternative interventions, such as folate supplementation, demonstrate cost-effective prevention benefits, Alan Garber, MD/PhD, Stanford University, says in an editorial in the May 16 Annals of Internal Medicine. Garber comments on two studies published in the Annals that found statin drugs were most cost-effective when used for secondary prevention. For primary prevention, costs of using statins in younger persons with few risk factors and no previous heart attack were high, the study authors conclude. Drug costs could be a factor considered by FDA's advisory committees in July as they discuss Mevacor and Pravachol for OTC use in individuals with no established cardiovascular disease or diabetes (1"The Tan Sheet" May 15, p. 3)

You may also be interested in...



Kerry Could Look To Kessler To Help Tap FDA Head; Wood A Possibility?

Former FDA Commissioner David Kessler may figure prominently in the selection of a new commissioner in the event that a Kerry administration takes over the White House in November

Kerry Could Look To Kessler To Help Tap FDA Head; Wood A Possibility?

Former FDA Commissioner David Kessler may figure prominently in the selection of a new commissioner in the event that a Kerry administration takes over the White House in November

Kerry Could Look To Kessler To Help Tap FDA Head; Wood A Possibility?

Former FDA Commissioner David Kessler may figure prominently in the selection of a new commissioner in the event that a Kerry administration takes over the White House in November

Related Content

Topics

UsernamePublicRestriction

Register

PS091269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel